TLR9-mediated ARF6 activation is involved in advancing CpG ODN cellular uptake

Communicative and Integrative Biology

Volumn 5, Issue 4, 2012, Pages 316-318

  Wu, Jing Yiing ^a   Kuo, Cheng Chin ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ADP ribosylation factor 6; CpG oligodeoxynucleotides; Innate immunity; ODN uptake; Toll like receptor 9 signaling

Indexed keywords

EID: 84869831987     PISSN: 19420889     EISSN: 19420889     Source Type: Journal    
DOI: 10.4161/cib.20182     Document Type: Article

References (16)

1. D'Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol 2006; 7:347-58; http://dx.doi.org/10.1038/nrm1910
2. Wu JY, Kuo CC. Pivotal role of ADP-ribosylation factor 6 in Toll-like receptor 9-mediated immune signaling. J Biol Chem 2012; 287:4323-34; http://dx.doi.org/10.1074/jbc.M111.295113
3. Kline JN, Waldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, Thorne PS, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160:2555-9;
4. Shirota H, Sano K, Hirasawa N, Terui T, Ohuchi K, Hattori T, et al. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J Immunol 2001; 167:66-74;
5. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev 2008; 60:795-804http://dx.doi.org/10.1016/j.addr.2007.12.004
6. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-84; http://dx.doi.org/10.1038/nrd2059
7. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117:1184-94; http://dx.doi.org/10.1172/JCI31414
8. Hennessy EJ, Parker AE, O'Neill LA. Targeting Tolllike receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9:293-307; http://dx.doi.org/10.1038/nrd3203
9. Häcker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 1998; 17:6230-40; http://dx.doi.org/10.1093/emboj/17.21.6230
10. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5:190-8; http://dx.doi.org/10.1038/ni1028
11. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor. Semin Immunol 2004; 16:17-22; http://dx.doi.org/10.1016/j.smim.2003.10.009
12. Guo LH, Schluesener HJ. Binding and uptake of immunostimulatory CpG oligodeoxynucleotides by human neuroblastoma cells. Oligonucleotides 2004; 14:287-98; http://dx.doi.org/10.1089/oli.2004.14.287
13. Peters PJ, Hsu VW, Ooi CE, Finazzi D, Teal SB, Oorschot V, et al. Overexpression of wild-type and mutant ARF1 and ARF6: distinct perturbations of nonoverlapping membrane compartments. J Cell Biol 1995; 128:1003-17; http://dx.doi.org/10.1083/jcb.128.6.1003
14. Dascher C, Balch WE. Dominant inhibitory mutants of ARF1 block endoplasmic reticulum to Golgi transport and trigger disassembly of the Golgi apparatus. J Biol Chem 1994; 269:1437-48;
15. Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 2008; 223:271-83; http://dx.doi.org/10.1111/j.1600-065X.2008.00630.x
16. Saitoh S, Miyake K. Regulatory molecules required for nucleotide-sensing Toll-like receptors. Immunol Rev 2009; 227:32-43; http://dx.doi.org/10.1111/j.1600-065X.2008.00729.x 318